Maria A. Voronkova,Heather L. Hansen,Madison P. Cooper,Jacob Miller,Narayanasami Sukumar,Werner J. Geldenhuys,Aaron R. Robart,Bradley A. Webb,Maria A Voronkova,Heather L Hansen,Madison P Cooper,Werner J Geldenhuys,Aaron Robart,Bradley Webb

Abstract:Metabolic reprogramming, including increased glucose uptake and lactic acid excretion, is a hallmark of cancer. The glycolytic "gatekeeper" enzyme phosphofructokinase-1 (PFK1), which catalyzes the step committing glucose to breakdown, is dysregulated in cancers. While altered PFK1 activity and expression in tumors have been demonstrated, little is known about the effects of cancer-associated somatic mutations. Somatic mutations in PFK1 inform our understanding of allosteric regulation by...

Cancer-associated somatic mutations in human phosphofructokinase-1 reveal a critical electrostatic interaction for allosteric regulation of enzyme activity